Wilmington, DE – Ufovax, a spin-off vaccine company from Scripps Research, announced today that the company has successfully extended its patented one component self-assembling protein nanoparticle (1c-SApNP) vaccine platform technology to a vaccine against the coronavirus SARS-CoV-2. The vaccine prototype features SARS-CoV-2 protein spikes protruding… [Read more]
U.S. Patent & Trademark Office has allowed Scripps Research patent application HIV-1 GP140 Immunogens Comprising Modified NHR1 Regions That Stabilize Pre-fusion Conformations.
Ufovax holds exclusive rights to develop and commercialize vaccine for HIV using this patented technology.